Avaden

Quick links to important sections

Avaden

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Avaden

Understanding Avaden

Avaden is a pharmaceutical treatment designed for the management of specific conditions related to hormonal regulation. It belongs to a class of medications known as gonadotropin-releasing hormone (GnRH) analogues. The primary function of this medication is to modulate the production of certain hormones within the body, which can be necessary for various therapeutic goals.

Mechanism of Action

The active components in Avaden work by interacting with the pituitary gland. By providing a continuous rather than pulsatile stimulation of GnRH receptors, the medication eventually leads to a down-regulation of these receptors. This process results in a significant reduction in the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).

In turn, the decrease in these gonadotropins leads to a reduction in the production of secondary hormones, such as testosterone in males or estrogen in females. This suppression is often a central requirement in the management of hormone-sensitive clinical conditions.

Clinical Applications

Avaden is typically utilized in scenarios where the regulation or temporary cessation of sex hormone production is beneficial. These applications may include:

  • Hormone-Sensitive Oncology: Used in cases where the growth of certain cells is stimulated by naturally occurring hormones.
  • Gynecological Management: Employed for conditions where reducing estrogen levels can help manage tissue growth or symptoms.
  • Pediatric Endocrinology: Used in specific instances to manage the timing of hormonal development in children.

Administration and Form

This medication is developed as a long-acting formulation, intended to provide a steady release of the active ingredient over a specified duration. This delivery method is designed to maintain consistent hormonal suppression without the need for frequent daily intervention. The specific approach to treatment is determined based on the individual's clinical requirements and the underlying condition being addressed.

Regulatory References

  1. Birth control pills - combination: MedlinePlus Medical Encyclopedia

What side effects are possible with Avaden?

Possible side effects and safety information for Avaden

This section summarizes the adverse reactions and safety information documented in official governmental regulatory labeling for Avaden, which governs its use by healthcare professionals.

Adverse Reactions Overview

The adverse reactions associated with Avaden are classified by System-Organ Class and frequency based on clinical trial data and post-marketing surveillance, generally using the International Council for Harmonisation (ICH) frequency bands. The most Common (affecting ge 1/100 to <1/10 patients) and Very Common (affecting ge 1/10 patients) side effects typically involve Gastrointestinal disorders (e.g., nausea and vomiting) and Nervous system disorders (e.g., headache, dizziness).

Classification Examples of Adverse Reactions (System-Organ Class)
Very Common Nausea, Vomiting, Headache, Fatigue (General disorders)
Common Diarrhea, Insomnia, Skin Rash (Infections and infestations)
Uncommon / Rare Blood cell count changes, Hypersensitivity reactions

Serious and Clinically Significant Risks

Official labeling defines several serious adverse reactions that are considered Rare (affecting ge 1/10,000 to <1/1,000 patients) or Very Rare. These include reports of severe hepatic dysfunction (liver injury) and anaphylaxis (a severe allergic reaction). Due to the risk of hepatic dysfunction, routine monitoring of liver function tests is specified in the regulatory documents.

Safety Considerations and Restrictions

  • Contraindications: Avaden is formally contraindicated in individuals with a documented hypersensitivity to the drug's active substance or any of its components.
  • Population-Specific: Particular caution and/or dose adjustment may be necessary for patients with pre-existing renal or hepatic impairment, as determined by official pharmacokinetics data. The drug's safety profile has limited data in certain populations, such as pediatrics, requiring specific consideration.
  • Dose-Related Patterns: Regulatory documents note that the incidence of certain gastrointestinal events, particularly nausea, can be dose-dependent and may be more pronounced during the initial phase of treatment.

This summary reflects the official documentation regarding risks and safety limitations of Avaden, providing a factual basis for risk assessment without offering clinical advice or interpretation.

Overdose and Emergency Response

Avaden Overdose and When to Seek Help

The official overdose profile for Avaden (lorazepam) is primarily defined by escalating central nervous system (CNS) depression, progressing from less severe symptoms to life-threatening respiratory collapse.

Documented Overdose Manifestations

Symptoms of overdose documented in authoritative regulatory sources include:

  • CNS Depression: Somnolence, confusion, lethargy, and ataxia (impaired coordination).
  • Severe Outcomes: Dose-related profound sedation, respiratory depression, hypotension, coma, and death are the most serious possible outcomes.
  • Specific Factors: The risk of serious adverse outcomes is significantly increased when Avaden is misused, abused, or co-ingested with other CNS depressants, such as alcohol or opioids.

Immediate Emergency Action

Immediate medical attention must be sought if signs of overdose, such as profoundly slowed breathing, inability to wake up, or coma, are observed. The official management measures include general supportive care, such as establishing and maintaining a patent airway and monitoring vital signs.

Flumazenil is a benzodiazepine antagonist that may be used to reverse the effects. However, regulatory documents caution that the use of this reversal agent may precipitate acute, life-threatening withdrawal reactions, particularly seizures, in patients with physical dependence on the drug.

Patients who have experienced an overdose require continuous monitoring of their vital signs and overall condition.

Therapeutic Uses of Avaden

What Avaden Treats: Main Uses and Benefits

Avaden's therapeutic role includes support for symptomatic management and relevant long-term therapeutic areas for women of reproductive age. Combination birth control pills may assist with managing certain gynecological conditions.

The medication is commonly used to help with the prevention of pregnancy. Beyond contraception, it is relevant for easing symptoms related to heavy menstrual bleeding, intense menstrual cramping, and cycle irregularity. Furthermore, it is applied across domains involving systemic imbalance, such as moderate hormonal acne breakouts and severe pre-menstrual symptoms.

The use of this therapy contributes to improved comfort and stability during symptomatic periods. It supports patients during difficult episodes by easing distress and contributes to easing the overall symptom load. Continuous use may be part of symptomatic management by offering the supportive benefit of reducing the risk of developing ovarian and endometrial cancers.

Therapeutic Focus: Cycle Management
Avaden is applied in addressing issues of cycle irregularity, which may assist with maintaining a sense of stability when symptoms are more noticeable.

Regulatory References

  1. NIH MedlinePlus Medical Encyclopedia

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Avaden — Official Regulatory Information

This map details the population eligibility rules for Avaden, focusing only on information explicitly documented in the contraindications and restrictions sections of governmental regulatory labels.


Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed Women of reproductive age seeking prevention of pregnancy.
Populations for whom use is not recommended Breastfeeding women, due to the potential for decreased milk production and quality.
Populations for whom use is contraindicated Patients with current or history of vascular events, liver disease, or certain cancers.

Eligibility Classifications (High-Level)

Classification Official Regulatory Wording
Eligibility severity classification Contraindicated (absolute prohibition); Not Recommended (conditional restriction).
Eligibility-context constraints Thrombotic Risk Status; Malignancy History; Hepatic Function; Pregnancy Status.

Resulting Eligibility Structure

Official eligibility statements:

  • Avaden is contraindicated in women with a history of or current venous or arterial thromboembolic events (e.g., DVT, stroke) or known thrombogenic mutations.
  • The medicine is contraindicated in the presence of breast cancer or any other estrogen- or progestin-dependent neoplasia.
  • Use is contraindicated in patients with severe uncontrolled hypertension, migraine with aura, severe liver disease, or if pregnant.
  • The medicine is not recommended for women over age 35 who smoke or for postmenopausal women.
  • Use must be discontinued at least four weeks before and through two weeks after major surgery involving prolonged immobilization.

Connection to the overall eligibility profile Official regulatory documents define eligibility through absolute contraindications centered on vascular risk (thromboembolism, hypertension), hormonal malignancy risk, and hepatic function. These exclusions establish the population that must not use the medicine, while authorized use is established only for women of reproductive age.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Avaden (Estradiol/Gestodene) is primarily defined by pharmacokinetic interactions that alter the systemic exposure of its active components or affect co-administered drugs.

Contraindicated Combinations

Co-administration is officially prohibited with specific Hepatitis C combination regimens due to the documented risk of elevated liver enzymes (ALT). These include medicinal products containing Ombitasvir/Paritaprevir/Ritonavir with or without Dasabuvir, Glecaprevir/Pibrentasvir, or Sofosbuvir/Velpatasvir/Voxilaprevir.

Pharmacokinetic and Exposure Interactions

Medicinal products formally classified as hepatic enzyme inducers (e.g., certain anticonvulsants like Phenytoin or Carbamazepine, and anti-infectives like Rifampin) are documented to cause a reduction in the plasma concentrations of Avaden's hormonal components. This effect also applies to the herbal product St. John's Wort (Hypericum perforatum), a known enzyme inducer.

Conversely, Avaden can alter the plasma concentrations of co-administered drugs. Regulatory information documents that the exposure of certain medicines, such as Ciclosporin, may be increased, while the exposure of others, such as Lamotrigine, may be reduced. The estrogen component can also increase levels of thyroid-binding globulin, which may affect thyroid hormone measurements.

Mechanism of Action

Avaden (adenosine) is an endogenous nucleoside that functions as a non-selective agonist at purinergic receptors. Its primary site of action for systemic physiological modulation is the atrioventricular (AV) node in the cardiac conduction system, where it primarily targets the adenosine A1 receptor (A1).

The A1 receptor is coupled to an inhibitory G-protein (Gi). Agonist binding activates this protein, which subsequently inhibits the enzyme adenylate cyclase. This inhibition reduces the intracellular concentration of cyclic adenosine monophosphate (cAMP), leading to decreased activity of Protein Kinase A (PKA).

The intracellular cAMP/PKA cascade modulation results in two major ion channel effects: it inhibits the influx of calcium ions (Ca^2+) and enhances the efflux of potassium ions (K^+) through specific channels. The increased K^+ efflux hyperpolarizes the AV nodal cell membrane. The combination of hyperpolarization and reduced Ca^2+ influx suppresses the Ca^2+-dependent action potential.

This cellular process results in the delayed propagation of the electrical impulse through the AV node, which modulates systemic heart rhythm.

Dosage and Administration Information

The administration of Avaden, a Combined Oral Contraceptive (COC), is governed by a strict, cyclic daily regimen detailed to maintain consistent systemic concentrations of Gestodene and the estrogen component. The principles of use focus entirely on standardized procedural adherence.

Official Administration Guidelines

Category Official Instruction
Route of Administration Avaden is for oral use only and must be swallowed.
Dosing Schedule The regimen requires taking one tablet daily. This is a fixed-dose combination product, typically containing Gestodene 75 mug (0.075 mg).
Frequency and Schedule The medication is taken once daily following a 28-day cyclic pattern. This usually consists of 21 consecutive days of active hormone tablets followed by 7 consecutive days of non-active (placebo) tablets or a hormone-free interval.
Timing and Intake The tablet must be taken at approximately the same time every day to ensure stable drug levels. It may be taken without regard to meals.

Procedural Structure and Constraints

Tablets must be taken in the order directed on the blister packaging to follow the sequential pattern of active and non-active days. The timing of initiating treatment is procedurally constrained, as use should not be started earlier than 4 weeks postpartum in women who are not breastfeeding. Adherence to this fixed schedule is crucial, as requirements state that efficacy is compromised if an active tablet is missed or delayed by more than 12 hours.

Connection to the overall use protocol The instructions structure Avaden's use around a standardized, cyclic 28-day regimen intended for long-term administration. This protocol mandates daily oral intake at a fixed time to ensure continuous exposure to the hormones. All requirements, from the sequential tablet order to the explicit missed-dose rules, are procedural constraints defined to guide proper use.

Recent Clinical Evidence

Avaden: Overview of Studies for Estradiol and Gestodene

The clinical evaluation of combined hormonal contraceptives like Avaden focuses on measuring efficacy and understanding long-term effects. Research includes short-term and intermediate-term randomized controlled trials (RCTs), as well as extensive, long-term observational studies.

Evidence for Use in Preventing Pregnancy

Avaden was studied for examining contraceptive efficacy (the prevention of pregnancy) through numerous clinical trials and large-scale population studies. These studies primarily focused on two areas: the incidence of pregnancy and the measure of ovulation inhibition in healthy women. Research describes that studies reported measurements of pregnancy incidence rates (Pearl Index) within the studied populations. The rate of efficacy measurement is often sensitive to user adherence, which is an external factor not controlled in observational settings.


Evidence for Symptom Management and Acne

Research has explored Avaden’s role in conditions characterized by fluctuating symptoms, such as heavy menstrual bleeding, menstrual pain, and hormonal acne. Studies monitored objective changes in blood loss volume and measured objective changes in total acne lesion counts. Findings describe patterns observed in the studies where trials reported how symptoms evolved in the observed populations, noting measured changes in pain and skin outcomes. However, comparative evidence is often limited against other specific hormonal treatments for these indications, and follow-up durations were typically short to intermediate.


Long-Term Studies and Protective Effects

Long-term epidemiological cohort and case-control studies have examined outcomes related to systemic imbalance by tracking the incidence of specific cancers, namely ovarian and endometrial cancers, in cohorts of users compared to non-users. Analyses of observational data show patterns related to lower incidence rates for both cancers among study cohorts associated with combined pills. This evidence contributes to the broader evidence landscape, but certainty remains low regarding the direct causal relationship, as findings are based on observational settings.

Key Studies & References

  1. Combination Birth Control Pills: MedlinePlus Medical Encyclopedia (NIH)

Frequently Asked Questions (FAQ)

Common questions about Avaden (FAQ)


Q: Is Avaden the same kind of medicine as [similar drug name]?

Avaden is officially classified as a Combined Hormonal Contraceptive (CHC). According to the official product information, it contains the synthetic progestin Gestodene combined with an estrogen component. This classification defines its role as one type of birth control pill in a larger family of similar medications.


Q: Can Avaden cause changes in sleep patterns?

Official documentation for this type of medication lists Insomnia, which is difficulty sleeping, as a common adverse reaction in the safety profile. The documentation describes insomnia as a common adverse reaction.


Q: What should I do if I miss taking Avaden?

Regulatory instructions provide specific procedural steps based on when an active tablet was missed and how many were missed. The procedural steps for a missed tablet are detailed in the patient information leaflet. These specific instructions are crucial for maintaining the intended effect.


Q: Does Avaden affect blood pressure?

Official documents list hypertension, or high blood pressure, as a documented adverse reaction. Furthermore, the medicine is officially contraindicated, meaning its use is prohibited, in individuals who have severe uncontrolled high blood pressure.


Q: Are there any known interactions between Avaden and supplements like St. John's Wort?

Yes, official documents specify an interaction with the herbal product St. John's Wort (Hypericum perforatum). This supplement is documented as an enzyme inducer, and its use may cause a reduction in the plasma concentrations of the hormonal components in the pill.


Q: How long does Avaden stay in your system?

Official pharmacokinetics data indicates that the Gestodene component has an elimination half-life documented to be approximately 12 to 15 hours. This figure refers to the time it takes for half of the drug to be cleared from the body.


Q: Does Avaden cause changes in appetite or weight?

Regulatory documentation for this class of medicine includes weight gain as a documented adverse effect. However, some clinical studies described that body weight remained practically unchanged in the observed populations.


Q: What is the typical timeframe for seeing the full benefits of Avaden?

The official administration instructions for contraceptive efficacy state that the full effect is generally considered established after taking one active tablet daily for seven consecutive days. This applies when beginning the pill outside the first five days of the menstrual period.


Q: Can Avaden be used during pregnancy or while breastfeeding?

The medicine is formally contraindicated (must not be used) if a woman is pregnant. It is not recommended for nursing mothers as official information indicates it may decrease the production of breast milk and alter its quality.


Q: How long does the effect of Avaden last?

The consistent contraceptive effect of Avaden is dependent on adherence to the daily dosing schedule. Since the active components have a half-life of around 12 to 15 hours, the intended effect is maintained only by taking the medicine every day as instructed by administration guidelines.


Q: Is it common to feel tired when taking Avaden?

According to the official safety profile, Fatigue is listed as a common general disorder associated with the use of combined hormonal contraceptives. This means it is an effect documented to occur frequently in study populations.


Q: Are there any specific foods or drinks that interact with Avaden?

Official prescribing information states that the tablets may be taken without regard to meals. Regulatory documentation for this product does not list specific foods that are documented to be prohibited due to interaction.


Q: What happens if I stop taking Avaden suddenly?

Official information notes that a transient delay of ovulation after discontinuation can occur. This is an expected physiological change that may affect the return to natural fertility cycles.


Q: Can children or teenagers take Avaden?

The official indication is for use by women of reproductive age. The safety and efficacy have generally been established in post-pubertal adolescents who have already begun menstruating (reached menarche).


Q: Is there a generic version of Avaden available?

Generic versions of the active ingredients, Gestodene and the estrogen component, are marketed under various trade names by different manufacturers in various global regions. This is common for branded medications after patent expiration.


Q: Are the side effects of Avaden temporary or do they last the whole time I take it?

The official documentation does not provide a general guarantee on the duration of all side effects. However, the documentation notes that some adverse events, like nausea, may be more pronounced during the initial phase of treatment.


Q: Do Avaden tablets need to be stored in a special way?

Official documentation specifies that the product must be stored at temperatures at or below 25 C (77 F). Additionally, the tablets must be protected from light to maintain the integrity of the medication.


Q: Is it safe to drink alcohol while taking Avaden?

Official regulatory documents for this medication and similar combined oral contraceptives do not list alcohol as a direct interaction requiring prohibition or mandatory restriction. The official instructions for use do not include an explicit warning against alcohol consumption.


Q: Does Avaden affect laboratory test results?

Yes, official product information states that the estrogen component can increase levels of a substance called thyroid-binding globulin. This effect may in turn affect the results of certain thyroid function and other endocrine-related tests.


Q: Can Avaden interact with birth control pills?

Avaden is itself a Combined Oral Contraceptive (COC), which is a type of birth control pill. It is not generally intended to be taken concurrently with other hormonal contraceptives, as it is designed to be the sole hormonal therapy for the intended purpose.

How should Avaden be stored and disposed of?

Storage and Handling Requirements

Avaden (Quazepam) tablets must be stored at controlled room temperature, specifically 25 C (77 F), with permitted temperature excursions between 15 C and 30 C (59 F and 86 F). The product must be dispensed and kept in a tight, light-resistant container to protect the integrity of the medicine from environmental elements such as moisture and light.

Child Safety and Disposal

The official labeling mandates that Avaden must be stored in a safe place and kept out of the reach of children. Due to its classification as a Schedule IV Controlled Substance, disposal of any unused or expired tablets must be consistent with Federal and local requirements. Patients should consult a healthcare professional regarding the proper disposal methods, such as utilizing an official drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Avaden found in:

A-Z Index: